With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
What’s the full story? Leerink anticipates upward pressure on consensus expectations for Cobenfy (KarXT) and milvexian, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback